Last November, a 58-year-old project manager named Greg in Scottsdale sent his prescribing clinic a photo of his insulin syringe next to a freshly reconstituted tesamorelin vial. "I drew 40 units like the pharmacy said," he wrote, "but the internet says 20. Am I about to take double?" His clinic replied within the hour: he was fine. He had a 5 mg vial reconstituted in 1 mL. The internet post he'd read was about a 10 mg vial reconstituted in 2 mL. Same concentration, same 2 mg dose, different numbers on the barrel. Greg's confusion is the single most common question that comes through compounded peptide support lines, and it's a good entry point for a broader conversation about tesamorelin dosing.
The short answer: the FDA-approved dose, established in Phase III trials of Egrifta for HIV-associated lipodystrophy (Falutz J et al., NEJM 2007/2008), is 2 mg subcutaneously once daily. Most compounded tesamorelin protocols mirror this standard, though some clinicians drop to 1 mg daily for specific patient populations. Compounded tesamorelin is prescribed off-label by licensed pharmacies for adults under physician supervision; the FDA-approved indication is HIV-associated lipodystrophy.
Here's what you actually need to know about the dose, the math, and the practical decisions around it.
Why 2 mg Is the Default (and Why That Matters)
Tesamorelin is a stabilized analog of growth hormone releasing hormone. The 2 mg daily dose wasn't pulled from thin air. It came directly from the pivotal Phase III trials that got Egrifta approved, which demonstrated clinically meaningful visceral fat reduction at exactly this level.
For compounded use outside the HIV-lipodystrophy context, 2 mg remains the standard starting point for a simple reason: it's the only dose with solid trial data behind it. Lower doses haven't been validated for the same magnitude of effect. Higher doses haven't been studied for additional benefit. The 2 mg figure sits in a narrow sweet spot where the data actually exists.
My honest opinion? Until someone funds a proper dose-ranging study in non-HIV populations, 2 mg daily is the only number you can point to with a straight face. Everything else is educated guessing.
When Prescribers Drop to 1 mg
Not everyone starts at the full dose. Some clinicians prescribe 1 mg daily in specific cases:
- Patients under 130 pounds
- Adults over 65 who benefit from slower titration
- People with insulin resistance or borderline glucose dysregulation
- Patients with significant comorbidities
- Those who are anxious about side effects and want a lower on-ramp
The 1 mg dose produces a smaller GH pulse and proportionally smaller effects, but it also tends to come with a milder side effect profile in the early weeks. A common approach: start at 1 mg for two to four weeks, then bump to 2 mg if everything looks clean. Conservative and reasonable.
What about doses above 2 mg? The pivotal trials didn't study them. Side effects (edema, glucose elevation, IGF-1 creep) tend to climb faster than benefits at higher levels. Think of it like volume on a stereo: past a certain point, you're just adding distortion. Most experienced prescribers cap at 2 mg daily.
The Reconstitution Math That Trips Everyone Up
This is the part that generates the most panicked emails. Tesamorelin ships as a lyophilized powder, and you reconstitute it with bacteriostatic water. The catch is that different pharmacies send different vial sizes, and if you don't do the math for your specific vial, you'll end up like Greg.
Get provider-reviewed GLP-1 therapy
Side effects are manageable with the right support. A licensed provider can adjust your dose when you need it.
Start Free Assessment →Here's the most common setup. A 5 mg (5,000 mcg) vial, reconstituted with 1 mL of bacteriostatic water:
- Concentration: 5 mg/mL (or 5,000 mcg/mL)
- For a 2 mg dose: draw 0.4 mL (40 units on a U-100 insulin syringe)
- For a 1 mg dose: draw 0.2 mL (20 units on a U-100 insulin syringe)
Some compounders ship 10 mg vials with instructions to reconstitute in 2 mL. The concentration ends up identical. Other setups vary. Always follow the specific reconstitution instructions from your dispensing pharmacy, not a Reddit thread.
Use U-100 insulin syringes, 29 to 31 gauge, 5/16 inch or 1/2 inch needle. For a 2 mg dose at 5 mg/mL (40 units of volume), a 0.5 mL syringe with clear markings works best.
Where, When, and How to Inject
Injection sites: Tesamorelin goes subcutaneously into the fat layer. The lower abdomen (about two inches from the navel) is most common because absorption is consistent and you can reach it easily. Outer thigh and back of the upper arm also work. Rotate sides, left and right alternating nightly, to avoid lipohypertrophy.
Time of day: Bedtime is the most common protocol and aligns with the natural overnight GH pulse. Most published research used evening dosing. Some patients prefer morning injections for convenience, and there's limited clinical evidence showing one is clearly superior. What matters more than the hour is consistency. Same time each day produces a more predictable response and cleaner lab monitoring.
If you're combining tesamorelin with other GH-axis peptides like ipamorelin, bedtime dosing makes more physiological sense.
The food question: A high-carb or high-fat meal close to injection can blunt the GH pulse. The practical window: inject at least two hours after eating, and avoid food for 30 minutes after. For bedtime dosers, this aligns naturally with most people's schedules. Morning dosers should inject before breakfast.
Daily Dosing, Missed Doses, and the Cycling Question
Tesamorelin's half-life is roughly 25 to 38 minutes, longer than sermorelin's 12 minutes or so, but still short enough that daily dosing is needed for sustained effect. The visceral fat reduction documented in trials assumed daily administration for at least six months.
Some compounded protocols use a 5-days-on, 2-days-off schedule, borrowed from sermorelin practice. The evidence base for this pattern with tesamorelin specifically is thin. Most prescribers stick with daily dosing.
If you miss a single day, it's not a crisis. Skip it and resume at your normal time the next day. Don't double up. If you miss three or more days in a row, the cumulative benefit may be slightly delayed, but you don't need to restart from scratch.
How Your Doctor Decides (and What Labs They're Watching)
The dosing decision isn't made in isolation. Prescribers weigh:
- The clinical indication (HIV-lipodystrophy vs. off-label use)
- Baseline IGF-1 levels
- Age and body weight
- Comorbidities (diabetes, cardiovascular disease)
- Treatment goals (visceral fat reduction vs. general GH-axis support)
- How the patient tolerates the starting dose
- Cost (compounded vs. branded Egrifta)
Adjustments typically happen at the three-month mark, once IGF-1 has reached a steady state.
A reasonable monitoring schedule looks like this:
- Baseline: IGF-1, fasting glucose, HbA1c, lipid panel, comprehensive metabolic panel, blood pressure
- Three months: Repeat IGF-1, fasting glucose, HbA1c
- Six months: Full repeat panel, body composition assessment if available
- Annually thereafter
The target IGF-1 is the upper half of the age-adjusted normal range. Pushing it above normal is not the goal and increases risk. This is one area where more is definitively not better.
Long-Term Use: What We Know and Don't Know
The pivotal Egrifta trials ran for 26 weeks. Beyond that, the data gets sparse. In compounded practice, continuous use past six months is common for general GH-axis support. Some prescribers prefer structured six-month courses with breaks in between. The boring truth is that consistent monitoring matters more than any particular cycling pattern.
One thing the trial data does show clearly: the visceral fat reduction tends to hold with continued therapy and regress when you stop. Tesamorelin isn't a permanent reset; it's more like a thermostat that only works while it's plugged in.
Branded Egrifta vs. compounded tesamorelin: The active molecule is identical. Branded Egrifta uses the 2 mg standard, and compounded preparations typically follow suit. Reconstitution and storage details may differ between formulations, so always follow the instructions from your dispensing pharmacy.
Storage: Reconstituted tesamorelin should be refrigerated and is generally stable for 14 to 28 days, depending on the formulation. Bacteriostatic water (containing benzyl alcohol) prevents microbial growth, but it doesn't make the vial shelf-stable indefinitely.
FAQ
What is the standard tesamorelin dose? 2 mg subcutaneously once daily. This is the dose established in the Egrifta clinical trials (Falutz J et al., NEJM 2007/2008) and used in most compounded protocols.
Should I take tesamorelin in the morning or at night? Bedtime is most common and aligns with the natural overnight GH pulse. Consistency matters more than the specific time of day.
Can I take a lower dose? Yes. 1 mg daily is sometimes prescribed for smaller patients, older patients, or those who need more conservative titration. Lower doses produce proportionally smaller effects.
How long until tesamorelin works? IGF-1 changes are detectable within weeks. Visible visceral fat reduction typically requires 12 to 26 weeks of daily dosing.
What if I miss a day? Skip the missed dose and resume normally the next day. Do not double up.
Is a 5-on-2-off schedule effective? Some compounded protocols use this approach, but the clinical trial evidence specifically for tesamorelin is limited. Most prescribers recommend daily dosing for full effect.
---
Compounded tesamorelin is prescribed off-label for adults; the FDA-approved indication for the branded version (Egrifta) is HIV-associated lipodystrophy. Compounded tesamorelin is prepared by licensed pharmacies for individual patients based on a prescriber's clinical judgment. This article is educational only and does not constitute medical advice. Talk to a qualified clinician before starting any peptide therapy.
Related reading: Tesamorelin Benefits and Research | Tesamorelin Side Effects Explained | Tesamorelin Visceral Fat Protocol | Tesamorelin Monitoring Labs | Order Compounded Tesamorelin
---
Not FDA-approved. Compounded peptides are prepared by licensed 503A pharmacies for individual patients based on a prescriber's clinical judgment. FormBlends is not a medical practice. Individual results vary. Consult a licensed clinician before starting any peptide therapy.